WHY YOU SHOULD ATTEND THE CMHC
Take home key practical strategies
from the new treatment guidelines
and evidence-based solutions for
managing your complex patients
Preview cutting-edge products
and services featured in the CMHC
Exhibit Hall and Professional
Education
Decipher the most recent clinical
data to apply directly to your
practice
Connect with leading experts in
cardiometabolic health for answers
to your most urgent questions
EARN 27.5
UP
TO
CME/CE CREDITS
“This is my third time attending the
Cardiometabolic Health Congress.
Once again, the information given
was cutting-edge, clinically
relevant and readily applicable.
For sure, attending the CMHC
will be an annual event for my
continuing medical education.”
- Oscar Giron, MD (Mundelein, IL)
2 TITLE PAGE
“An excellent, multidisciplinary
Congress! I enjoyed learning of
late-breaking advances in care that
provide possible treatment options
for my patients.”
- Carina Katigbak, PhD (Boston, MA)
[
[
The 2014 Cardiometabolic Health Congress
will translate the latest medical research into
practical, clinical approaches for preventing, delaying, and
managing cardiovascular and metabolic risk.
“I find the CMHC provides
more useful clinical information
and evidence-based medicine
that I can apply to my practice
than all the pharmacy conferences
combined! This is my favorite
conference and I wish I could
attend every year!”
- Megan Undeberg, PharmD (Duluth, MN)
Boston, MA
9th Annual
TABLE OF CONTENTS
[
[
Join our renowned faculty – along with 44 prestigious medical associations
and 1,500 of your colleagues – as they present expert clinical perspectives,
frontline research and a complete educational experience addressing
today’s cardiometabolic disease epidemic.
Chairpersons & Faculty
4-5
Program Agenda
6-8
CME Symposia
8-10
Program Overview
11
Accreditation
11
Professional Education
12
Exhibitor Information
13
Hotel & Travel
14
Association Supporters
14
Publication Supporters
14
Registration Form
15
TITLE PAGE 3
CHAIRPERSONS & FACULTY
George L. Bakris, MD
Christie M. Ballantyne, MD
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Pritzker School of Medicine
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Methodist DeBakey Heart Center
Robert H. Eckel, MD
Jay S. Skyler, MD, MACP
Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics
Charles A. Boettcher II Chair in Atherosclerosis
Director, Discovery Translation
Colorado Clinical & Translational Science Institute
University of Colorado Anschutz Medical Campus
Director, Lipid Clinic, University Hospital
Professor of Medicine, Pediatrics, & Psychology
Division of Endocrinology, Diabetes & Metabolism
University of Miami Miller School of Medicine
Deputy Director for Clinical & Academic Programs
Diabetes Research Institute
Catherine Davis Ahmed
Jeffrey L. Anderson, MD
Caroline M. Apovian, MD
FH Advocate and Director of Outreach
The FH Foundation
Professor of Medicine
University of Utah School of Medicine
Associate Chief of Cardiology
Director, Cardiovascular Research
Intermountain Heart Institute
Intermountain Medical Center
Professor of Medicine
Boston University School of Medicine
Director
Center for Nutrition and Weight Management
Boston Medical Center
Jamy D. Ard, MD
Suzanne V. Arnold, MD, MHA
Louis J. Aronne, MD
Associate Professor, Div. of Public Health Sciences
Department of Epidemiology & Prevention
Wake Forest School of Medicine
Co-Director, Weight Management Center
Medical Director, Medical Weight Loss Program
Wake Forest Baptist Health
Clinical Scholar and Cardiologist
Saint Luke’s Mid America Heart Institute
Research Assistant Professor
Department of Biomedical & Health Informatics
University of Missouri-Kansas City
Sanford I. Weill Professor of Metabolic Research
Medical Director
Center for Weight Mgmt. & Metabolic Clinical Research
Weill-Cornell Medical College
Seth J. Baum, MD
Harold E. Bays, MD
Deepak L. Bhatt, MD, MPH
Medical Director, Women’s Preventive Cardiology
Christine E. Lynn Women’s Health & Wellness Institute
Boca Raton Regional Hospital
Voluntary Associate Professor of Medicine
Miller School of Medicine
University of Miami
Medical Director/President
Louisville Metabolic and Atherosclerosis
Research Center, Inc.
Professor of Medicine
Harvard Medical School
Executive Director
Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Heart and Vascular Center
Lawrence Blonde, MD
George A. Bray, MD
Eliot A. Brinton, MD
Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology
Ochsner Medical Center
Boyd Professor
Chief
Division of Clinical Obesity and Metabolism
Pennington Biomedical Research Center
Director
Atherometabolic Research
Utah Foundation for Biomedical Research
Rebecca J. Brown, MD
John B. Buse, MD, PhD
Samuel Dagogo-Jack, MD
Assistant Clinical Investigator
National Institute of Diabetes and Digestive
and Kidney Diseases
National Institutes of Health
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Care Center
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Professor of Medicine
Dir., Div. of Endocrinology, Diabetes & Metabolism
A. C. Mullins Chair in Translational Research
Director, General Clinical Research Center
Director, Endocrinology Fellowship Training Program
University of Tennessee Health Science Center
Edward R. Damiano, PhD
Michael H. Davidson, MD
Honey E. East
Associate Professor
Biomedical Engineering
Boston University
Clinical Professor
Director of the Lipid Clinic
The University of Chicago
Pritzker School of Medicine
Endocrinologist
Premier Medical Group of Mississippi
Sarah de Ferranti, MD, MPH
Keith C. Ferdinand, MD
JoAnne M. Foody, MD
Director
Preventive Cardiology Program
Assistant Professor of Pediatrics
Harvard Medical School
Professor of Clinical Medicine
Tulane University School of Medicine
Chair, National Forum for Heart
Disease and Stroke Prevention
Associate Professor
Harvard Medical School
Medical Director
Cardiovascular Wellness Program
Brigham and Women’s Hospital
Martha M. Funnell, MS, RN, CDE
Abhimanyu Garg, MD
Thomas Giles, MD
Associate Research Scientist
Department of Learning Health Sciences
University of Michigan Medical School
Professor of Internal Medicine
Chief
Division of Nutrition and Metabolic Diseases
University of Texas Southwestern Medical Center
Clinical Professor of Medicine
Heart and Vascular Institute
Tulane University School of Medicine
Scott M. Grundy, MD, PhD
Robert A. Harrington, MD
Terry A. Jacobson, MD
Director, Center for Human Nutrition
Distinguished Professor of Internal Medicine
University of Texas Southwestern Medical Center
Assistant Chief, Research in the Medical Service
Veterans Affairs Medical Center
Arthur L. Bloomfield Professor of Medicine
Chairman of the Department of Medicine
Stanford University
President, National Lipid Association
Professor of Medicine
Emory University
Director
Office of Health Promotion & Disease Prevention
Co-Director, Lipid & CV Risk Reduction Program
Grady Health Systems
Michael D. Jensen, MD
C. Ronald Kahn, MD
Lee M. Kaplan, MD, PhD
Thomas J. Watson, Jr.
Professor in Honor of Dr. Robert L. Frye
Mayo College of Medicine
Director, Department of Medicine
Obesity Treatment Research Program
Mayo Clinic
Mary K. Iacocca Professor
Harvard Medical School
Chief Academic Officer
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Director
Obesity, Metabolism & Nutrition Institute
Massachusetts General Hospital
4 CHAIRPERSONS & FACULTY
Sekar Kathiresan, MD
William E. Kraus, MD
Peter Libby, MD
Associate Professor of Medicine
Harvard Medical School
Director, Preventive Cardiology
Massachusetts General Hospital
Professor of Medicine
Duke University School of Medicine
Mallinckrodt Professor of Medicine
Harvard Medical School
Chief of Cardiovascular Medicine
Brigham and Women’s Hospital
Colleen M. Majewski, MD
Michael Miller, MD
Mark E. Molitch, MD
Assistant Professor of Medicine
Section of Endocrinology, Diabetes & Metabolism
The University of Chicago Medicine
Endocrinologist
Duchossois Center for Advanced Medicine
Professor of Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology
Metabolism and Molecular Medicine
Northwestern University
Feinberg School of Medicine
Patrick M. Moriarty, MD
Pamela B. Morris, MD
Dariush Mozaffarian, MD, DrPH
Director
Atherosclerosis/LDL-Apheresis Center
Professor of Medicine
University of Kansas Medical Center
Director
Seinsheimer Cardiovascular Health Program
Co-Director, Women’s Heart Care
Medical University of South Carolina
Dean, Friedman School of Nutrition Science & Policy
Tufts University
Sunder Mudaliar, MD
Elif A. Oral, MD
Aldo J. Peixoto, MD
Clinical Professor of Medicine
University of California, San Diego
Associate Professor of Internal Medicine
Director, Post-Bariatric Surgery Clinic
Medical Director
University of Michigan Hospital & Health Systems
Bariatric Surgery Program
Professor of Medicine, Nephrology
Yale School of Medicine
Associate Chair, Ambulatory Operations & Quality
Department of Internal Medicine
Clinical Chief, Section of Nephrology
Director, Yale Hypertension Center
Richard E. Pratley, MD
Gary A. Puckrein, PhD
Scott Radabaugh
Director, Florida Hospital Diabetes Institute
Senior Scientist, Translational Research Institute
for Metabolism and Diabetes
Professor
Sanford Burnham Medical Research Institute
Chief Executive Officer
National Minority Quality Forum
FH Advocate
The FH Foundation
Daniel M. Riche, PharmD, BCPS, CDE
Paul M. Ridker, MD, MPH
Francesco Rubino, MD
Associate Professor of Pharmacy Practice
The University of Mississippi School of Pharmacy
Associate Professor of Medicine
The University of Mississippi Medical Center
Clinic Coordinator, Cardiometabolic Clinic
Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular
Disease Prevention
Brigham and Women’s Hospital
Professor and Chair
Bariatric & Metabolic Surgery
King’s College London, UK
Marc S. Sabatine, MD, MPH
Sidney C. Smith, Jr., MD
Virend K. Somers, MD, PhD
Chairman, TIMI Study Group
Associate Physician in Cardiovascular Medicine
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Professor of Medicine
Director
Center for Cardiovascular Science and Medicine
The University of North Carolina in Chapel Hill
Professor of Medicine
Mayo Clinic
Consultant in Cardiovascular Diseases
Mayo Clinic and Mayo Foundation
Laurence S. Sperling, MD
P. Gabriel Steg, MD
Evan Stein, MD, PhD
Professor of Medicine (Cardiology)
Director, Emory Heart Disease Prevention Center
Emory University School of Medicine Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health at Emory University
Professor, Cardiology Department
Paris Diderot University
Director, Coronary Care Unit
Hospital Bichat-Claude Bernard
Director Emeritus
Metabolic & Atherosclerosis Research Center
Neil J. Stone, MD
Peter H. Stone, MD
Andra Stratton
Bonow Professor of Medicine
Feinberg School of Medicine, Northwestern University
Suzanne & Milton Davidson Distinguished Physician
Medical Director
Vascular Center of the Bluhm CV Institute
Northwestern Memorial Hospital
Associate Professor of Medicine
Harvard Medical School
Co-Director, Samuel A. Levine Cardiac Unit
Director, Clinical Trials Center
Brigham and Women’s Hospital
Co-Founder and President
Lipodystrophy United
Joshua Thaler, MD, PhD
Peter J. Turnbaugh, PhD
James A. Underberg, MD
Assistant Professor
Division of Metabolism, Endocrinology & Nutrition
University of Washington Department of Medicine
Assistant Professor
Department of Microbiology & Immunology
G.W. Hooper Research Foundation
University of California, San Francisco
Clinical Assistant Professor of Medicine
NYU Medical School
NYU Center for CVD Prevention
Director, Bellevue Hospital Lipid Clinic
Kris Vijay, MD
Thomas A. Wadden, PhD
Michael A. Weber, MD
Vice President
Scottsdale Cardiovascular Center
Clinical Professor of Medicine
University of Arizona College of Medicine
Professor of Psychology
Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Director, Center for Weight and Eating Disorders
Professor of Medicine
State University of New York
Downstate College of Medicine
Matthew R. Weir, MD
Howard A. Wolpert, MD
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Senior Physician
Joslin Diabetes Center
CHAIRPERSONS & FACULTY 5
PROGRAM AGENDA
Professional Education (non-CME)
These non-certified activities are not part of the official CMHC program and are planned solely by the sponsoring organizations/companies.
Wednesday, October 22, 2014
11:15am – 12:30pm
The Effect of a Once-Weekly Therapy on
A1C and Weight Over 3 Years
Neil I. Kaminsky, MD
Sponsored by AstraZeneca Diabetes
12:30 – 2:00pm • Lunch
Advancing Paradigm Changes in
Type 2 Diabetes Management
Robert Busch, MD
Sponsored by Janssen Pharmaceuticals, Inc.
2:00 – 3:15pm
Addressing Chronic Weight Management
with Targeted Pharmacotherapy
Harold E. Bays, MD
Sponsored by Eisai, Inc.
3:15 – 4:30pm
Understanding High Triglycerides
JoAnne M. Foody, MD
Sponsored by AstraZeneca
4:30 – 5:45pm
SGLT2 Inhibition: A Glucuretic Treatment Option
for Your Adult Patients With Type 2 Diabetes
Neil I. Kaminsky, MD
Sponsored by AstraZeneca Diabetes
5:45 – 7:00pm
Chronic Weight Management in Adults:
A Treatment Option
Harold E. Bays, MD
Sponsored by Takeda Pharmaceuticals America, Inc.
For session details, see page 12.
Wednesday, October 22, 2014 (cont.)
7:00 – 8:30pm • Dinner
New Diagnostic Tools for the Prevention and
Comprehensive Management of Diabetes
Timothy E. Graham, MD
Sponsored by Health Diagnostic Laboratory, Inc.
Friday, October 24, 2014
6:00 – 7:00pm
Take a Closer Look at Homozygous
Familial Hypercholesterolemia
Daniel E. Wise, MD
Sponsored by Aegerion Pharmaceuticals
6:00 – 7:00pm
Treatment Considerations for
Generalized Lipodystrophy
Jean Chan, MD
Sponsored by AstraZeneca
Thursday, October 23, 2014
6:15 – 7:45am
CME Breakfast Symposia A, B
12:45 – 2:15pm
CME Lunch Symposia A, B, C
SESSION I:
DYSLIPIDEMIA, ATHEROSCLEROSIS AND
CARDIOVASCULAR DISEASE RISK REDUCTION
2:30 – 3:30pm
Expert Debates in Antithrombotic Therapy
8:00 – 8:10am
Opening Remarks
Christie M. Ballantyne, MD
8:10 – 9:40am
CVD Prevention Guidelines Update:
Clinical Impact and Current Controversies
Christie M. Ballantyne, MD (moderator); George L. Bakris, MD;
Robert H. Eckel, MD; Scott M. Grundy, MD, PhD;
Jay S. Skyler, MD; Sidney C. Smith, Jr., MD; Neil J. Stone, MD
· Do diabetic patients with CAD need more than just aspirin?
· Should patients with stents receive DAPT for more than a year?
· Should patients with AFib receive novel anticoagulants?
Deepak L. Bhatt, MD, MPH; Robert A. Harrington, MD; P. Gabriel Steg, MD
3:30 – 4:15pm
Afternoon Break/Exhibit Hall
4:15 – 4:45pm
Keynote Session
Implications of Recent Genetic Findings on
Management of Cardiovascular Risk
Sekar Kathiresan, MD
9:40 – 10:30am
Keynote Session
Update on Inflammation in the Pathogenesis
of Cardiometabolic Disease
Peter Libby, MD
Testing the Inflammation Hypothesis:
The CIRT and CANTOS Trials
Paul M. Ridker, MD, MPH
10:30 – 11:30am
Morning Break/Exhibit Hall
4:45 – 5:45pm
Clinical Controversies in Lipid Management:
Case-Based Presentations and Discussion
Christie M. Ballantyne, MD (moderator); Robert H. Eckel, MD;
JoAnne M. Foody, MD; Sekar Kathiresan, MD; Neil J. Stone, MD
5:45pm
Closing Remarks
Christie M. Ballantyne, MD
5:45 – 7:00pm
11:30am – 12:30pm
Late-Breaking Clinical Trials and FDA Update
Christie M. Ballantyne, MD (moderator);
Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD;
Keith C. Ferdinand, MD; Jay S. Skyler, MD
Join us in the Exhibit Hall
for our Welcome Reception
7:00 – 9:00pm
CME Dinner Symposia A, B
Agenda and faculty are subject to change.
6 PROGRAM AGENDA
)
For CME Symposia details, see pages 8 – 10.
Friday, October 24, 2014
6:15 – 7:45am
CME Breakfast Symposia A, B, C
SESSION II:
HYPERTENSION AND CARDIO-RENAL SYNDROME
SESSION III:
DIABETES MANAGEMENT
8:00 – 8:10am
Opening Remarks
George L. Bakris, MD
2:00 – 2:30pm
Is Alzheimer’s Disease Type 3 Diabetes?
C. Ronald Kahn, MD
8:10 – 8:40am
Low Diastolic BP and Progression to CKD
Aldo J. Peixoto, MD
2:30 – 3:00pm
Type 2 Diabetes Management 2014
John B. Buse, MD, PhD
8:40 – 9:10am
Device Therapy and Resistant Hypertension
George L. Bakris, MD
3:00 – 3:30pm
Initiating and Monitoring Insulin Therapy
Howard A. Wolpert, MD
9:10 – 9:40am
New Methodologies for the Management of
Hyperkalemia in Kidney Disease
Matthew R. Weir, MD
3:30 – 4:15pm
Afternoon Break/Exhibit Hall
4:15 – 4:45pm
The Bionic Pancreas
Edward R. Damiano, PhD
9:40 – 10:10am
The Contribution of Aldosterone in
Obesity-Related Hypertension
Colleen M. Majewski, MD
4:45 – 5:45pm
Diabetes Panel Session
Jay S. Skyler, MD (moderator); John B. Buse, MD, PhD;
Edward R. Damiano, PhD; C. Ronald Kahn, MD;
Howard A. Wolpert, MD
10:10 – 11:15am
Morning Break/Exhibit Hall
11:15am – 12:15pm
Clinical Controversies in Hypertension Management
George L. Bakris, MD (moderator); Colleen M. Majewski, MD;
Aldo J. Peixoto, MD; Matthew R. Weir, MD
12:30 – 2:00pm
CME Lunch Symposia A, B, C
Agenda and faculty are subject to change.
“A++ program. Better than some
ADA and AADE programs. I especially
enjoy the general sessions, group
presentations and discussions.”
- Judith Pentedemos, FNP (Ayer, MA)
5:45pm
Closing Remarks
Jay S. Skyler, MD
6:00 – 7:00pm
Professional Education A, B (non-CME)
7:00 – 9:00pm
CME Dinner Symposia A, B
“This is the CME I have been
looking for! Excellent combinations
of basic science and clinical practice,
as well as endocrinology and
cardiology grouping.
I truly feel educated.”
“As a primary care physician,
if I could attend only
one conference each year, the
CMHC would be that conference.”
- Atul Soreng, MD (Bangor, ME)
- Jun Liang, MD (Savage, MN)
PROGRAM AGENDA 7
PROGRAM AGENDA
Saturday, October 25, 2014
6:15 – 7:45am
CME Breakfast Symposium
SESSION IV:
LIFESTYLE AND OBESITY MANAGEMENT
8:00 – 8:10am
Opening Remarks
Robert H. Eckel, MD
8:10 – 8:50am
Impact of Gut Microbiota on Obesity and CVD Risk
Peter J. Turnbaugh, PhD
8:50 – 9:30am
Long-Term Effects of Metabolic Surgery
Lee M. Kaplan, MD, PhD; Francesco Rubino, MD
9:30 – 10:00am
Sleep Apnea and Restricted Sleep Patterns:
Impact on Cardiometabolic Health
Virend K. Somers, MD, PhD
10:00 – 10:15am
Morning Break
10:15 – 11:00am
Long-Term Use of Obesity Medications:
How to Sustain Weight Loss
Caroline M. Apovian, MD
11:00 – 11:30am
Behavioral Strategies in Obesity Management
Thomas A. Wadden, PhD
11:30 – 11:50am
Role of Exercise in the Modulation of Nontraditional
CHD Risk Factors
William E. Kraus, MD
11:50am – 12:30pm
Obesity Panel Discussion
Robert H. Eckel, MD (moderator); Caroline M. Apovian, MD;
Lee M. Kaplan, MD, PhD; William E. Kraus, MD;
Francesco Rubino, MD; Virend K. Somers, MD, PhD;
Peter J. Turnbaugh, PhD; Thomas A. Wadden, PhD
12:30pm
Closing Remarks
Robert H. Eckel, MD
Agenda and faculty are subject to change.
CME SYMPOSIA
Participate in your choice of 16 CME symposia held each day of the Congress. Symposia include meals or refreshments and are ticketed
events that fill up quickly. Register for CMHC today to sign up for these value-added CME/CE activities—at no additional cost!
Thursday, October 23, 2014
CME Breakfast Symposium A • 6:15 – 7:45am
The Triglycerides Conundrum:
Practical Clinical Guidance for Reducing Residual CV Risk
Harold E. Bays, MD (Chair); Eliot A. Brinton, MD; Scott M. Grundy, MD, PhD
Hypertriglyceridemia is an increasingly relevant issue facing clinicians in their
routine practice. Our faculty will address current controversies in triglyceride
management and provide expert insight on how to effectively manage
persistently elevated triglycerides in patients who remain at high CV risk. This
symposium will evaluate triglyceride-lowering therapies, with a focus on
omega-3 fatty acids, comparing and contrasting data on their safety,
tolerability, lipid-lowering effects and cardio-protective benefits.
CME Lunch Symposium A • 12:45 – 2:15pm
Obesity Management 2014: New Perspectives and
Therapeutic Options for a Growing Problem
Robert H. Eckel, MD (Chair); Jamy D. Ard, MD;
George A. Bray, MD; Michael D. Jensen, MD
Type 2 diabetes and obesity are very much intertwined and treatment
of each disease affects the other. This symposium will explore obesity’s
biologic causes, clinical consequences, and the expanding armamentarium
of weight control methods, especially in those special populations affected
by prediabetes and diabetes. Clinicians will refine their ability to evaluate
comorbidities and select obesity therapies that are safe, effective and
individualized for patient needs.
Supported by an educational grant from Amarin Pharma, Inc.
Supported by an educational grant from Novo Nordisk, Inc.
CME Breakfast Symposium B • 6:15 – 7:45am
Confronting Racial and Ethnic
Disparities in Cardiometabolic Disease
Laurence S. Sperling, MD (Chair); Gary A. Puckrein, PhD;
Keith C. Ferdinand, MD; JoAnne M. Foody, MD; Kris Vijay, MD
Multiple mechanisms interact in complex ways to contribute to health status,
including social class, genetics, personal health behavior and utilization of medical
care. Our faculty will provide systemic approaches to reduce disparities and proven
clinical strategies to combat cardiometabolic disease in ethnic minority populations.
This symposium is jointly provided by the American College of Cardiology, in
collaboration with the National Minority Quality Forum and Association of Black
Cardiologists.
Sponsored by the American College of Cardiology in collaboration with the National
Minority Quality Forum and the Association of Black Cardiologists | Supported in
part by educational grants from Arbor Pharmaceuticals and Merck & Co.
CME Lunch Symposium B • 12:45 – 2:15pm
Closing the Gaps in the Continuum of Care for Patients
with Acute Coronary Syndromes: Implications for Optimal Antiplatelet Use
Deepak L. Bhatt, MD, MPH (Chair); Jeffrey L. Anderson, MD;
Robert A. Harrington, MD; P. Gabriel Steg, MD
The manifestations of Acute Coronary Syndrome (ACS) are associated with
high morbidity and mortality. This symposium will provide an update on
major U.S. guideline recommendations concerning the use of P2Y12 inhibitors
in patients with ACS. Our faculty of internationally recognized experts will
present and analyze clinical trial data on the available P2Y12 inhibitors,
with an emphasis on clinical data in high-risk patients such as the elderly,
those with diabetes, and those with a prior history of stroke. Attendees will
leave this activity better able to individualize antiplatelet therapy, improve
outcomes and minimize hospital readmission rates.
Supported by an educational grant from AstraZeneca
8 PROGRAM AGENDA / CME SYMPOSIA
rs
CME SYMPOSIA
Thursday, October 23, 2014 (continued)
Friday, October 24, 2014
CME Lunch Symposium C • 12:45 – 2:15pm
Evolving Strategies for LDL-Lowering: Novel Target and
Treatments for CVD Risk Reduction
Terry A. Jacobson, MD (Chair); Eliot A. Brinton, MD; Sekar Kathiresan, MD;
Evan A. Stein, MD, PhD
CME Breakfast Symposium A • 6:15 – 7:45am
Optimizing Antihypertensive Therapies in High-Risk and
Difficult-to-Treat Patients with Hypertension
George L. Bakris, MD (Chair); Keith C. Ferdinand, MD;
Thomas Giles, MD; Michael A. Weber, MD
The latest CVD prevention guidelines published by national organizations have
diverted significantly from previous recommendations in that they abandoned
target goals for lipid parameters in favor of focusing on statin treatment for
high-risk patients. While statins remain first-line therapy in LDL-C reduction,
patients continue to experience residual risk or are unable to tolerate statins.
Despite well-established risks, hypertension remains under-treated and,
when treated, often stubbornly difficult to control. This symposium seeks to
improve guideline adherence and help clinicians integrate antihypertensive
therapies into the management of high-risk patient populations including
the elderly (those 65 and older), African Americans, patients suffering from
heart failure, the obese, and individuals with diabetes and/or the metabolic
syndrome. Case-based clinical scenarios and a panel discussion will clarify
how best to integrate effective therapies into the management of patients
with hypertension to reduce global cardiometabolic risk and improve clinical
outcomes.
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals
CME Dinner Symposium A • 7:00 – 9:00pm
The Wide Spectrum of Familial Hypercholesterolemia:
Discovering Your Highest Risk Patients and Optimizing Treatment
Seth J. Baum, MD (Chair); Catherine Davis Ahmed; Sarah de Ferranti, MD, MPH;
Patrick M. Moriarty, MD; Pamela B. Morris, MD; Scott Radabaugh
Worldwide, there are at least 20 million people with familial hypercholesterolemia
(FH). Despite the availability of effective treatment options and the prevalence of
the disease, FH is both underdiagnosed and undertreated. This symposium will
address knowledge and practice gaps in the identification and management of
patients with severe FH. The faculty will provide expert recommendations for
diagnosing FH and cascade family screening, and will present the most current
evidence on novel therapeutic options. Patient Advocates from The FH Foundation
will share their personal experiences with this life-threatening disease and efforts to
improve awareness and encourage proactive treatment.
Supported by educational grants from Aegerion Pharmaceuticals, Inc. and
Genzyme, A SANOFI COMPANY | Endorsed by The FH Foundation
CME Dinner Symposium B • 7:00 – 9:00pm
Novel and Emerging Combinations to Achieve Glycemic Control and Reduce
Cardiometabolic Risk: A Focus on Incretin-Based Therapy and SGLT2 Inhibitors
George L. Bakris, MD (Chair); Mark E. Molitch, MD;
Sunder Mudaliar, MD; Richard E. Pratley, MD
Newer treatment options, including sodium glucose co-transporter-2 (SGLT2)
inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1
(GLP-1) receptor agonists, and several fixed-dose combinations are available or
are under development and may change the treatment paradigm for T2DM. These
evidence-based therapies have the potential to work synergistically in combination
with other available interventions to achieve glycemic control and to reduce
overall cardiometabolic risk for individuals with T2DM. This symposium will keep
clinicians apprised of new clinical trial data and developments and discuss how to
appropriately integrate these newer and emerging therapies into clinical practice.
Supported by an educational grant from AstraZeneca
Supported by an educational grant from Forest Laboratories, Inc.
CME Breakfast Symposium B • 6:15 – 7:45am
Innovations in GLP-1 Receptor Agonist Therapy:
Individualized Treatment Strategies to Overcome Barriers and Reduce
Cardiometabolic Risk in Type 2 Diabetes Mellitus
John B. Buse, MD, PhD (Chair); Samuel Dagogo-Jack, MD; Richard E. Pratley, MD
Some of the newer Type 2 diabetes therapies, including GLP-1 receptor
agonists, do not carry the same limitations as traditional therapies. This class
of drugs has been shown to improve global cardiometabolic risk factors and
to improve the function of beta cells, rather than just address hyperglycemia.
Our faculty will help clinicians understand the differences between GLP-1
receptor agonists, not only in terms of their mechanisms of action, but in
terms of their impact on glucose control, beta cell function, and cardiovascular
risk factors such as body weight, blood pressure, and lipid profiles. A review
of current guideline recommendations will help clinicians appropriately
integrate this class of medications into clinical practice to improve outcomes
in the management of type 2 diabetes.
Supported by an educational grant from Lilly USA, LLC
CME Breakfast Symposium C • 6:15 – 7:45am
New Targets and Treatments for LDL Lowering: Role of PCSK9 Inhibitors
Christie M. Ballantyne, MD (Chair); Michael H. Davidson, MD;
Marc S. Sabatine, MD, MPH; James A. Underberg, MD
Hypercholesterolemia is a major risk factor for cardiovascular diseases,
increasing the incidence of myocardial infarction and death. However,
patients on statin therapy who fail to reach their LDL-C treatment
goal due to intolerance, poor therapeutic response, or severe familial
hypercholesterolemia have few effective therapeutic options. Recent genetic
insights have revealed novel therapeutic mechanisms that provide further
LDL-C reductions on top of statin therapy. PCSK9 inhibitors are an emerging
drug class designed to target and suppress the PCSK9 protein that prevents
the body from removing LDL cholesterol from the bloodstream.
Supported by an educational grant from Amgen
Only 2014 CMHC participants may register for
CME Symposia & Professional Education.
Seating is limited and available on a first-come,
first-serve basis. Register today!
See page 15
CME SYMPOSIA 9
CME SYMPOSIA
Friday, October 24, 2014 (continued)
CME Lunch Symposium A • 12:30 – 2:00pm
Triglyceride and Mixed Dyslipidemia Management:
The Changing Landscape of CV Risk Reduction
Christie M. Ballantyne, MD (Chair); Terry A. Jacobson, MD;
Michael Miller, MD; Dariush Mozaffarian, MD, DrPH
CME Dinner Symposium A • 7:00 – 9:00pm
Improving Awareness and Outcomes in Lipodystrophy Syndromes:
Clinical Manifestations, Diagnosis, and Evolving Therapeutic Strategies
Abhimanyu Garg, MD (Chair); Rebecca J. Brown, MD;
Elif A. Oral, MD; Andra Stratton
Triglycerides are an increasingly important consideration when assessing
cardiovascular risk. This symposium will address the prevalence of untreated
hypertriglyceridemia and the importance of managing triglycerides to
reduce cardiovascular risk. Recognized experts will discuss current guideline
recommendations for hypertriglyceridemia and present data on new and
emerging treatment options with a focus on comparing and contrasting
the clinical data on prescription omega-3 fatty acids and novel combination
therapies.
This symposium, endorsed by Lipodystrophy United (LU), will discuss the
signs and symptoms of lipodystrophy, a rare disorder characterized by
selective loss of adipose tissue. If not adequately treated, patients with
lipodystrophy remain at risk for severe life‐threatening complications and
chronic morbidity, such as pancreatitis, end-stage liver or renal disease,
accelerated atherosclerosis, and cardiomyopathy. The faculty will explain
the metabolic consequences of the disease and present evidence-based
treatment recommendations. A Lipodystrophy United Patient Advocate
will provide the unique perspective of an individual living with the
disease to help overcome common barriers to early recognition and
treatment.
CME Lunch Symposium B • 12:30 – 2:00pm
New Frontiers in Obesity Management:
Advances in Neurobiological Treatment Strategies
Caroline M. Apovian, MD (Chair); Louis J. Aronne, MD;
Lee M. Kaplan, MD, PhD; Joshua Thaler, MD, PhD
New discoveries related to physiologic neuroendocrine mechanisms that
mediate appetite regulation and energy balance as well as the relationship
between obesity and related comorbidities have created a need for
education. This symposium will review the recent advances in knowledge
regarding the neurobiological basis of obesity, the complexities of central
nervous system (CNS) involvement, and how new and emerging therapeutic
options work with the CNS to regulate body weight. Attendees will receive
guidance on how to select obesity therapies that are safe, effective, and
individualized to support obese patients during various stages of weight
loss.
Supported by an educational grant from Takeda Pharmaceuticals
International, Inc., US Region and Orexigen
CME Lunch Symposium C • 12:30 – 2:00pm
Individualizing Therapy in Patients with Stable Ischemic Heart Disease:
Managing the Full Spectrum of Comorbidities and Cardiometabolic
Risk Factors
JoAnne M. Foody, MD (Chair); Suzanne V. Arnold, MD;
Deepak L. Bhatt, MD, MPH; Peter H. Stone, MD
Approximately 10 million individuals in the U.S. have angina, with 500,000
new cases being diagnosed each year. Cardiovascular risk reduction
for patients with Stable Ischemic Heart Disease (SIHD) should focus on
appropriate evaluation and diagnosis of symptoms to guide treatment
and management of concomitant risk factors. This symposium will review
the updated guidelines for the diagnostic and treatment of patients with
SIHD, with a focus on select comorbidities, such as gender, heart failure,
and diabetes. Faculty will also discuss appropriate risk-stratification and
decision-making strategies to determine which patients should receive
revascularization and which patients should be managed with medication.
Supported by an educational grant from Gilead Sciences, Inc.
Supported by an educational grant from AstraZeneca | Endorsed by
Lipodystrophy United
CME Dinner Symposium B • 7:00 – 9:00pm
Integrated Management of the Complexities of Cardiometabolic
Diseases: A Patient-Centric Team Approach
Lawrence Blonde, MD; Honey E. East, MD;
Martha M. Funnell, MS, RN, CDE; Daniel M. Riche, PharmD
Implementation of the Patient Protection and Affordable Care Act has
increased the emphasis on collaboration and teamwork in chronic
disease management, the medical home and patient self-management.
This unique symposium will discuss the challenges of managing the
complex cardiometabolic patient and ways in which a multidisciplinary
team approach with a focus on patient empowerment can reduce
morbidity/mortality and improve long-term patient outcomes. Expert
faculty will provide case examples demonstrating strategies for providing
integrated care to type 2 diabetes patients with multiple risk factors.
Supported by an educational grant from Merck & Co., Inc.
Saturday, October 25, 2014
CME Breakfast Symposium • 6:15 – 7:45am
Overcoming Obstacles in Obesity Management:
New Tools, Techniques, and Treatment Strategies
Louis J. Aronne, MD (Chair); Caroline M. Apovian, MD;
Harold E. Bays, MD; Thomas A. Wadden, PhD
Lifestyle interventions focused on diet, physical activity and behavioral
therapy are essential to treating obesity and should be incorporated
throughout the continuum of care. While some individuals do manage
to lose weight through diet and lifestyle changes, long-term weight loss
and maintenance is difficult to achieve for many. New and emerging
pharmacologic therapies have the potential to significantly impact the
management of obesity and reduce the associated cardiometabolic risk.
During this symposium, expert faculty will review the mechanisms of
action and clinical and safety profiles of prescription weight loss agents,
describe effective patient counseling techniques for achieving and
maintaining weight loss, and provide techniques to develop a weight
and complications-centric approach to obesity management.
Supported by an educational grant from Eisai, Inc.
Agenda and faculty are subject to change.
Check cardiometabolichealth.org for updates and final symposia options.
10 CME SYMPOSIA
PAGE
TITLEOVERVIEW
PROGRAM
Statement of Need*
The ever-increasing presence of cardiometabolic risk
continues to be a major challenge for health care
professionals in the United States. The prevalence of most
cardiometabolic risk factors – especially hyper
tension,
diabetes, and obesity – continues to rise. In the years ahead,
American physicians should expect to treat unprecedented
numbers of patients at high risk for morbidity and mor
tality
from cardiovascular disease. In 2000, approximately 32% of
U.S. adults had the metabolic syndrome, a constellation of
cardiometabolic risk factors including excessive abdominal
fat, insulin resistance, dyslipidemia, and hyper
tension.
In more recent years that fi gure has climbed to 34%, and it
may even be as high as 38%, depending on the criteria used
to defi ne the syndrome.
Target Audience & Learning Objectives
The CMHC is designed for advanced-level clinicians
responsible for the prevention, diagnosis, and
management of cardiometabolic risk.
At the end of the congress, par
1.
2.
3.
Patients with multiple cardiometabolic risk factors have twice
the likelihood of developing and dying from cardiovascular
disease and more than seven times the risk of developing
diabetes, compared to those with no cardiometabolic risk
factors. As the number of these patients increases, the
burden of cardiovascular disease can be expected to increase
in the United States as well. Unfor tunately , cardiovascular
disease already aff ects approximately 82.6 million U.S. adults
and is the leading cause of U.S. deaths. According to the
American Hear t Association, cardiovascular disease causes
more than 800,000 deaths each year – more than cancer and
accidents combined. This is an average of more than 2,200
deaths per day , or one death ever y 39 seconds.
Conclusion
PROGRAM OVERVIEW
Supported by an educational grant from AstraZeneca
Health care professionals play a major role in stemming
the future burden of cardiovascular disease, diabetes, and
associated comorbidities by employing aggressive strategies
for the early identifi cation and comprehensive management
of patients presenting with multiple cardiometabolic risk
factors. The 2014 Cardiometabolic Health Congress will
translate the latest cutting- edge medical research into
practical, clinical approaches for preventing, delaying, and
managing cardiovascular and metabolic risk
. The goal is
to provide the medical community with evidence
-based
inter ventions to improve health outcomes and quality
of life for the growing numbers of patients at increased
cardiometabolic risk.
* To access the 2014 CMHC full statement of need and reference list, please
visit www .cardiometabolichealth.org/2014/accreditation.asp
10 TITLE PAGE
4.
ticipants will be able to:
Explain the interrelationships among the various
cardiometabolic risk factors, their impact on
cardiovascular health, and their common comorbidities.
Translate evidence-based strategies for prevention,
screening, and treatment of cardiometabolic risk factors
and their comorbidities to their clinical practice.
CMHCincluding
participants
may registe
IdentifyOnly
which 2013
inter ventions,
lifestyle changes
and various drugs in combination,
most appropriate
Seating is are
limited
and available on
for par ticular patients based on their risk profi les.
Identify how novel and emerging therapies can be
integrated into clinical practice to reduce morbidity and
mor tality from cardiovascular and metabolic disease.
Purpose Statement
To improve patient outcomes through early identification
and inter vention strategies for patients with, or at risk of
developing, diabetes and cardiovascular disease.
PROGRAM OVERVIEW & ACCREDITATION
Statement of Need
Physician Credit
The ever-increasing presence of cardiometabolic risk continues to be a
major challenge for health care providers in the United States. Current
estimates suggest approximately 23% to 38% of all U.S. adults have
metabolic syndrome, a constellation of cardiometabolic risk factors,
including excessive abdominal fat, insulin resistance, inflammation,
dyslipidemia, and hypertension. Patients with multiple cardiometabolic
risk factors have twice the likelihood of developing and dying
from cardiovascular disease and more than seven times the risk of
developing diabetes compared with those with no cardiometabolic
risk factors. Cardiovascular disease already affects approximately 83.6
million U.S. adults (greateer than 1 in 3) and is the leading cause of U.S.
deaths; however, this CVD burden can be expected to increase.
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council
for Continuing Medical Education through the joint providership of
Medical Education Resources and HealthScience Media, Inc.
Medical Education Resources is accredited by the ACCME to provide
continuing medical education for physicians.
This sampling of sobering statistics points to a rapidly growing
epidemic of cardiovascular and metabolic disease and calls to the
forefront the need for medical education focused on all aspects of
cardiometabolic risk. The CMHC presents an especially valuable venue
for this educational outreach with sessions fostering a collaborative,
multidisciplinary approach to care.
AAFP
(American Academy of Family Physicians) Credit
The 2014 Cardiometabolic Health Congress will translate the latest
cutting-edge medical research into practical, clinical approaches for
preventing, delaying, and managing cardiovascular and metabolic risk.
The goal is to provide the medical community with evidence-based
interventions to improve health outcomes and quality of life for the
growing numbers of patients at increased cardiometabolic risk.
Credit Designation
Medical Education Resources designates this live activity for a
maximum of 27.5 AMA PRA Category 1 Credits™. Physicians should claim
only the credit commensurate with the extent of their participation in
the activity.
This Live activity, Cardiometabolic Health Congress, with a beginning
date of 10/22/2014, has been reviewed and is acceptable for up to 27.50
Prescribed credit(s) by the American Academy of Family Physicians.
Physicians should claim only the credit commensurate with the extent
of their participation in the activity.
Nursing Credit (ANCC)
Medical Education Resources is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center’s
Commission on Accreditation.
Target Audience & Learning Objectives
This CE activity provides 27.5 contact hours of continuing nursing
education.
At the end of the Congress, participants will be able to:
Medical Education Resources is a provider of continuing nursing
education by the California Board of Registered Nursing, Provider #CEP
12299, for 27.5 contact hours.
The CMHC is designed for advanced-level clinicians responsible for the
prevention, diagnosis, and management of cardiometabolic risk.
1.
Explain the interrelationships among the various cardiometabolic
risk factors, their impact on cardiovascular health, and their
common comorbidities.
AANP
(American Academy of Nurse Practitioners) Credit
This program is approved for 27.5 contact hour(s) of continuing
education (which includes 22.0 hours of pharmacology) by the
American Association of Nurse Practitioners. Program ID 1408362. This
program was planned in accordance with AANP CE Standards
and Policies and AANP Commercial Support Standards.
2.
Translate evidence-based strategies for prevention, screening, and
treatment of cardiometabolic risk factors and their comorbidities
to their clinical practice.
3.
Identify which interventions, including lifestyle changes and
various drugs in combination, are most appropriate for particular
patients based on their risk profiles.
Registered Dietitian Credit
Identify how novel and emerging therapies can be integrated
into clinical practice to reduce morbidity and mortality from
cardiovascular and metabolic disease.
Pharmacy Credit
4.
Purpose Statement
To improve patient outcomes through early identification and
intervention strategies for patients with, or at risk of developing,
diabetes and cardiovascular disease.
Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance,
independence, objectivity, and scientific rigor in all of its educational
activities. In accordance with this policy, MER identifies conflicts of
interest with its instructors, content managers, and other individuals
who are in a position to control the content of an activity. Conflicts
are resolved by MER to ensure that all scientific research referred to,
reported, or used in a CME activity conforms to the generally accepted
standards of experimental design, data collection, and analysis. MER
is committed to providing its learners with high-quality activities that
promote improvements or quality in health care and not the business
interest of a commercial interest.
Medical Education Resources is an accredited CPE provider for the
Commission on Dietetic Registration.
Medical Education Resources (MER) is accredited by the
Accreditation Council for Pharmacy Education as a provider
of continuing pharmacy education. MER designates this
continuing education activity for 27.5 contact hours (2.75
CEUs) of the Accreditation Council for Pharmacy Education. (Universal
Program Number – 0816-9999-14-002-L01-P)
Physician Assistants: AAPA accepts certificates of participation for
educational activities certified for Category I credit from AOACCME,
Prescribed credit from AAFP and AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical
society. The 2014 Cardiometabolic Health Congress (CMHC) is
accredited by Medical Education Resources (MER). MER is accredited by
the ACCME, ANCC, ACPE, and the CDR to provide continuing medical
education. Physician Assistants may receive a maximum of 27.5 hours of
Category I credit for completing this program.
Certified Diabetes Educators: The 2014 Cardiometabolic Health
Congress (CMHC) is accredited by Medical Education Resources (MER).
MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide
continuing medical education. All of these accredited organizations are
recognized by the AADE when applying for CDE renewal of certification
or for initial certification.
PROGRAM OVERVIEW & ACCREDITATION 11
PROFESSIONAL EDUCATION (non-CME)
Round out your CMHC educational experience by attending Professional Education symposia focused on novel therapies
and diagnostic testing. These non-certified activities are not part of the official CMHC program and are planned solely by
the sponsoring organizations/companies. There are no fees to attend and meals or refreshments may be provided.
WEDNESDAY • OCTOBER 22, 2014
FRIDAY • OCTOBER 24, 2014
11:15am – 12:30pm
The Effect of a Once-Weekly Therapy on A1C
and Weight Over 3 Years
Neil I. Kaminsky, MD
6:00 – 7:00pm
Take a Closer Look at Homozygous
Familial Hypercholesterolemia
Sponsored by AstraZeneca Diabetes
12:30 – 2:00pm • Lunch
Advancing Paradigm Changes in
Type 2 Diabetes Management
Robert Busch, MD
Daniel E. Wise, MD
Sponsored by Aegerion Pharmaceuticals
6:00 – 7:00pm
Treatment Considerations for Generalized Lipodystrophy
Jean Chan, MD
Sponsored by AstraZeneca
Sponsored by Janssen Pharmaceuticals, Inc.
2:00 – 3:15pm
Addressing Chronic Weight Management
with Targeted Pharmacotherapy
Harold E. Bays, MD
FACULTY
Sponsored by Eisai, Inc.
3:15 – 4:30pm
Understanding High Triglycerides
JoAnne M. Foody, MD
Harold E. Bays, MD
Robert Busch, MD
Medical Director/President
Louisville Metabolic and Atherosclerosis
Research Center, Inc.
Endocrinologist
The Endocrine Group
Jean Chan, MD
JoAnne M. Foody, MD
Endocrinologist
San Diego, CA
Associate Professor
Harvard Medical School
Medical Director
Cardiovascular Wellness Program
Brigham and Women’s Hospital
Timothy E. Graham, MD
Daniel Wise, MD
Assistant Professor of Medicine,
Endocrinology, Diabetes, and Metabolism,
Biological Chemistry, and Nutrition
Cardiology Specialists of the Carolinas PA
Sponsored by AstraZeneca
4:30 – 5:45pm
SGLT2 Inhibition: A Glucuretic Treatment Option for
Your Adult Patients With Type 2 Diabetes
Neil I. Kaminsky, MD
Sponsored by AstraZeneca Diabetes
5:45 – 7:00pm
Chronic Weight Management in Adults: A Treatment Option
Harold E. Bays, MD
Sponsored by Takeda Pharmaceuticals America, Inc.
7:00 – 8:30pm • Dinner
New Diagnostic Tools for the Prevention and
Comprehensive Management of Diabetes
Timothy E. Graham, MD
Sponsored by Health Diagnostic Laboratory, Inc.
Arrive Early for a Chance to
win an iPad Mini or an iMac!
Check-in at the CMHC Registration desk by
11:00am on Wednesday, October 22
to be entered into this exclusive raffle.
12 PROFESSIONAL EDUCATION
Neil I. Kaminsky, MD
Endocrinologist
Presbyterian Medical Group
Albuquerque, NM
2014 EXHIBITORS
(as of October 8, 2014)
Aegerion Pharmaceuticals
Amarin Pharma Inc.
American College of Cardiology
Amgen Inc.
Arbor Pharmaceuticals
AstraZeneca
AstraZeneca Diabetes
Atherotech Diagnostics Lab
Boston Heart Diagnostics
Cardiometabolic Health Congress
Cardio Renal Society of America
Cell Science Systems
diaDexus, Inc.
Eisai, Inc.
Enovative Technologies
Genova Diagnostic
Genzyme, A SANOFI COMPANY
Gilead Sciences, Inc.
Health Diagnostic Laboratory, Inc.
Healthy Habits Medical Consultants
Ideal Protein of America
Janssen Pharmaceuticals, Inc.
Lilly
LipoScience
Meet the Experts Lounge
Merck & Co., Inc.
Metabolic Medical Institute, Inc.
Nature-Throid
Novo Nordisk, Inc.
Otsuka America Pharmaceutical, Inc.
Postgraduate Medicine
Salix Pharmaceuticals, Inc.
Takeda Pharmaceuticals U.S.A., Inc.
The FH Foundation
WHY THE CMHC
is the Premier
Sponsorship Opportunity…
ACCESS
High-level US-based practicing clinicians – the
decision makers on the front lines of patient care
and cardiometabolic risk management
ENGAGE
Multidisciplinary clinical experts seeking
cutting-edge products and services to help
manage patients suffering from cardiovascular
and metabolic diseases
INTERACT
2014 SPONSORS
The CMHC gratefully acknowledges the sponsorship provided
by the following organizations:
Platinum Sponsor
AstraZeneca Diabetes
Silver Sponsors
AstraZeneca
Eisai
Health Diagnostic Laboratory, Inc.
With our world-renowned faculty and collaborate
with your key customers in a unique setting
BUILD
Meaningful relationships with your current
and future customers to help grow your brand
through face-to-face discussions
Customized Sponsorship Packages Available
The most exposure for less with an integrated
marketing package designed to suit your needs
Bronze Sponsors
Amgen
Merck
Novo Nordisk, Inc.
Takeda Pharmaceuticals U.S.A., Inc.
For information on becoming a 2014 CMHC sponsor
please call 877.571.4700 or email [email protected]
EXHIBITOR INFORMATION 13
HOTEL & TRAVEL
Sheraton Boston Hotel
39 Dalton Street
Boston, MA 02199
617.236.2000
To book your hotel room by phone, please contact the
hotel directly. Mention that you have registered to attend
the Cardiometabolic Health Congress to receive our
special negotiated room rate.
The 2014 CMHC discounted room rate is available only
until October 15, 2014, on a first-come, first-served basis.
Rooms are limited and subject to availability.
To reserve your hotel accommodations online, visit
www.cardiometabolichealth.org/travel.asp
Faneuil Hall
Boston is a center for medical and scientific discoveries that offers historical ambience, beautiful
autiful parks,
and great shopping and dining. This city truly has something for everyone:
•
Follow the Freedom Trail on foot to learn about the historical people and events surrounding
unding
the Revolutionary War, including Paul Revere and his famous ride to Lexington.
•
g on Boston’s
B
Spend the day strolling through Boston Common, the oldest U.S. city park, or shopping
trendy Newbury Street.
•
See the historic architecture in Faneuil Hall and grab lunch and souvenirs in Quincy Market.
arrket.
tion: www.bostonus
sa.
a.co
com
co
m
Visit Boston’s official Convention and Visitors Bureau website for more sightseeing information:
www.bostonusa.com
Association Supporters
American Heart Association
Councils on High Blood Pressure Research;
Stroke; Epidemiology & PrevenƟon;
CV Disease in the Young; Basic CV Sciences;
Clinical Cardiology; CV and Stroke Nursing;
Lifestyle and Cardiometabolic Health
Association of
Physicians Assistants
in Cardiology
Metropolitan New York Association
of Diabetes Educators
New Jersey CoordinaƟng
Body of AADE
San Francisco Bay Area
AssociaƟon of Diabetes Educators
14 HOTEL & TRAVEL / SUPPORTERS
Publication Supporters
LAST CHANCE TO SAVE UP TO $300
Register by 10/3/2014
2014
Online:
www.cardiometabolichealth.org
Fax:
866.218.9168
Scan:
Scan this code to
call us directly
Mail Registration Form with Payment:
Cardiometabolic Health Congress
c/o HealthScience Media, Inc.
788 Shrewsbury Avenue, Suite 102
Tinton Falls, NJ 07724
Phone:
877.571.4700
732.758.0030 – outside the USA
Special Online
Only Pricing
Register By
Register By
Registration Fees
10/16/2014
10/21/2014
$795
$695
$300
$1,295
$850
$750
$325
$1,350
Physicians*
Allied Health Professionals*
Residents/Fellows**
Industry
Register Onsite
beginning 10/22/2014
$895
$795
$350
$1,395
* Must be engaged in clinical practice to receive discounted rate.
** ID card from school, residency, or fellowship program is required for verification. No other discounts apply.
Prefix
First Name
Last Name
Degree(s)
Title
Affiliation
Address 1
Address 2
City
State
Tel
Fax
Email
NPI # (required)
Please indicate your specialty: (check one)
Cardiology
Endocrinology
Internal Medicine
Nephrology
Which best describes your primary workplace setting? (check one)
Office-based
Hospital
Academic
Government
Zip Code
Primary Care
Pharmacy
Industry
Other
Industry
Current members of our Association Supporters receive a $100 discount off the registration price.
Indicate which organization you are a member of below:
Alliance of Cardiovascular Professionals (ACVP)
American Academy of Pediatrics (AAP)
American Association of Heart Failure Nurses (AAHFN)
American Board of Obesity Medicine (ABOM)
American College of Cardiology (ACCF)
American College of Nutrition (ACN)
American College of Preventive Medicine (ACPM)
American Heart Association (AHA)
American Medical Women’s Association (AMWA)
American Society of Bariatric Physicians (ASBP)
American Society of Endocrine Physician Assistants (ASEPA)
American Society of Hypertension (ASH)
Asian Pacific Society of Cardiology (APSC)
Association of Black Cardiologists (ABC)
Association of Occupational Health Professionals in Healthcare (AOHP)
Association of Physician Assistants in Cardiology (APAC)
Cardio Renal Society of America (CRSA)
Consortium for Southeastern Hypertension Control (COSEHC)
Connecticut Alliance of Diabetes Educators (CADE)
Coordinating Body of AADE of Massachusetts (DEEM)
European Society of Lifestyle Medicine (ESLM)
Foundation of European Nurses in Diabetes (FEND)
Granite State Diabetes Educators (GSDE)
International Association for the Study of Obesity (IASO)
International Atherosclerosis Society (IAS)
International Society on Hypertension in Blacks (ISHIB)
Latino Diabetes Association (LDA)
Metropolitan New York Association of Diabetes Educators (MNYADE)
National Association of Bariatric Nurses (NABN)
National Association of Chronic Disease Directors (NACDD)
National Board of Physician Nutrition Specialists (NBPNS)
National Kidney Foundation (NKF)
NJ Coordinating Body of AADE (NJCB)
Northern Indiana Association of Diabetes Educators (NIADE)
Obesity Action Coalition (OAC)
San Francisco Bay Area Assoc. of Diabetes Educators (SFBAADE)
Society for the Study of Ingestive Behavior (SSIB)
Society of Cardiovascular Computed Tomography (SCCT)
Society of Invasive Cardiovascular Professionals (SICP)
STOP Obesity Alliance (STOP)
The Obesity Society (TOS)
World Heart Federation (WHF)
Total Amount Due
Method of Payment
Check
Visa
MasterCard
American Express
Discover
Account Number
Expiration Date
Cardholder Name
Cardholder Signature
Cancellation Policy
Cancellations must be made in writing via fax to 866.218.9168 or email to [email protected]. Refunds, less a $100 service fee, will be given if written
cancellation is received no later than August 22, 2014. No refunds will be given after August 22, 2014. To send a substitute, please call 877.571.4700 or email
your request to [email protected].
REGISTRATION FORM 15